ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

LQDA Liquidia Corporation

12.70
-0.09 (-0.70%)
07 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Liquidia Corporation NASDAQ:LQDA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.09 -0.70% 12.70 12.60 13.75 13.085 12.67 12.79 698,507 01:00:00

Liquidia Corporation to Host 2020 Financial Results Conference Call on March 23, 2021

09/03/2021 12:30pm

GlobeNewswire Inc.


Liquidia (NASDAQ:LQDA)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Liquidia Charts.

Liquidia Corporation (NASDAQ: LQDA) today announced that 2020 financial results will be reported on Tuesday, March 23, 2021. The company will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and provide a corporate update.

The live call may be accessed by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 5167825. A live and archived webcast of the call will be available on the Events & Presentations page of Liquidia’s website.

About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT technology. The Company operates through two subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies is developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH), and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. Liquidia PAH, LLC provides commercialization for rare disease pharmaceutical products, such as Treprostinil Injection, Sandoz Inc.’s first-to-file, generic treprostinil for PAH.

Liquidia Corporation is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

Contact InformationMedia & Investors:Jason AdairVice President, Corporate Development and Strategy919.328.4400jason.adair@liquidia.com

1 Year Liquidia Chart

1 Year Liquidia Chart

1 Month Liquidia Chart

1 Month Liquidia Chart

Your Recent History

Delayed Upgrade Clock